NewcelX Ltd. (NCEL) 12-Month Stock Forecast & Price Target Cone

Per the Roarable RQD rating, NCEL scores 30 out of 100, grade E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are: Fundamental Cash Engine 5/20 (ROIC -35%; FCF yield -17.84%); Whale 13F Flow 5/20 (institutional accumulation and options positioning); Insider Conviction 3/20 (SEC Form 4 and Congressional PTR cluster flow); Macro Regime Fit 7/20 (Beta 1.0; sector sensitivity); and Forensic Balance Sheet 10/20 (Altman Z 2.5; Piotroski F 1/9; Debt/Equity 0.5).

Read together, the pillars point to weak cash generation as the dominant issue. The two lowest-scoring pillars, cash engine and insider conviction, indicate that the business is consuming cash and that insider activity in the source data does not offer support. The balance sheet pillar sits at the middle of the range, with a Z-Score of 2.5 and a Piotroski F-Score of 1/9, which signals weak financial health on the nine-point scale. For a prospective investor, the upside case rests almost entirely on a turnaround in cash generation that the current data does not show, while the valuation case is complicated by the absence of earnings-based multiples in the source data. The rating's stated verdict is avoidance, and the supporting facts in this dossier are consistent with that framing.

Per the SEC financials, all three periods report operating and net losses, with revenue at $0.0M, and gross, operating, and net margins are each 0% per the market data. ROIC is -35% per the market data. The Altman Z-Score of 2.5 and Piotroski F-Score of 1/9 are cited in the Roarable RQD rating, and Debt/Equity of 0.5 is also taken from that section. The source data does not provide a full reconciliation of these scores, so their components are not verifiable here.

Per the recent news and catalysts feed, four items reference NCEL. The most recent is a Yahoo Finance UK item on seasonal returns, marked YELLOW. A Benzinga pre-market roundup listing health care movers is also marked YELLOW. A third item, a Q2 2026 earnings headline, reports a wider-than-expected loss per share accompanying a 7.45% share price gain; it is marked GREEN and classed as a CATALYST, and its source attribution in the feed is an unrelated domain, which limits how much weight the item can bear. A Traders Union price-prediction piece is marked YELLOW. The feed does not provide the underlying text of these items. Per the Butterfly Supply-Chain Graph, no supply-chain links or proprietary signals are present; the sector is Health Care and the supply chain is listed as NONE.

Risk watch items from the feed are the reported loss-per-share widening noted in the Q2 2026 headline and the absence of any signal in the Butterfly graph.

Per the Butterfly Supply-Chain Graph, the supply chain is NONE, with no butterfly links and no proprietary signals. The source data therefore does not establish upstream or downstream dependencies, sector correlations beyond the stated beta of 1.0, or second-order bottlenecks. A prospective investor should note that the absence of mapped links is itself a data limitation rather than evidence of independence.

• What products or clinical programs generate or are expected to generate revenue, given $0.0M reported revenue across three fiscal years?
• What is the source of the cash balance and funding that would offset annual free cash outflows of $-2.8M in FY 2025?
• Does the Q2 2026 loss-per-share figure and the source attribution of that headline reflect a reliable earnings report?
• What are the debt terms behind the reported Debt/Equity of 0.5 when period-level debt is listed as N/A?
• What EPS, P/E, and EV/EBITDA figures would apply once earnings are reported, given that all earnings-based multiples are currently absent?